NovaBay Pharmaceuticals Inc.
NBY
AMX
Sector: Healthcare
Industry: Biotechnology
0.11
USD
0.00
(-1.93%)
Optionable: No Market Cap: 7 M 90-day average vol: 1001150.0
Previous close: 0.109 Open: 0.11 Bid: 0.1071 Ask: 0.1071
52 week range
0.10 0.63
Last updated: Friday 7th October 2022
Get Access to 1 Billion Usable Market data points IN YOUR EXCEL SHEETS WITH EASY TO USE EXCEL FUNCTIONS
Get started todaySearch for a stock
Are you?
Metrics
Valuation
Price per Sales TTM ($) | 0.84 |
Price per Book TTM ($) | 0.48 |
PE Ratio (TTM) | -1.00 |
Book Value per Share ($) | 0.28 |
5 Year PE Range | -7.4 , -1.3 |
Returns
7 Day Return | -3.26% | |
1 Month Return | -51.61% | |
3 Month Return | -64.72% | |
1 Year Return | -80.91% | |
3 Year Return | -82.31% | |
5 Year Return | -97.66% | |
YTD Return | -71.61% |
Risk
Financial Health
Technicals
RSI (14 Day) | 22.25 |
14 Day SMA ($) | 0.11 |
14 Day EMA ($) | 0.12 |
Money Flow Index | 52.25 |
Average True Range | 0.02 |
50 Day SMA ($) | 0.21 |
200 Day SMA ($) | 0.26 |
ADX | 22.15 |
MACD | -0.03 |
Growth
Free Cash Flow QoQ Growth | -17.97% |
Free Cash Flow YoY Growth | 0.00% |
Revenue YoY Growth | 0.00% |
EPS QoQ Growth | 0.00% |
Revenue QoQ Growth | 15.82% |
EPS YoY Growth | 0.00% |
Profitability
News
Financials
NBY Income Statement
Annual
| Dec-12 | Dec-13 | Dec-14 | Dec-15 | Dec-16 | Dec-17 | Dec-18 | Dec-19 | Dec-20 | Dec-21 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 7 M | 3 M | 1 M | 4 M | 12 M | 18 M | 13 M | 7 M | 10 M | 8 M |
| Cost of sales | -333000 | -152000 | 254000 | 1 M | 2 M | 3 M | 1 M | 2 M | 4 M | 3 M |
| Gross operating profit | 7 M | 61000 | 198000 | 3 M | 9 M | 15 M | 11 M | 5 M | 6 M | 6 M |
| Selling Gen & administrative expense | 6 M | 6 M | 8 M | 19 M | 19 M | 22 M | 19 M | 14 M | 12 M | 14 M |
| Research & development expense | 9 M | 12 M | 9 M | 6 M | 1 M | 410000 | 259000 | 184000 | 285000 | 44000 |
| Operating income | -8 M | -15 M | -17 M | -21 M | -11 M | -7 M | -8 M | -9 M | -6 M | -9 M |
| floaterest income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| floaterest expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other income net | 1 M | -554000 | 2 M | 2 M | -2 M | -89000 | 1 M | -252000 | -5 M | 3 M |
| Pre-tax Income (EBT) | -7 M | -16 M | -15 M | -19 M | -13 M | -7 M | -7 M | -10 M | -11 M | -6 M |
| Income taxes | 2000 | 2000 | 2000 | 2000 | 2000 | 3000 | 4000 | 6000 | 5000 | 0 |
| Net income from total operations | -7 M | -16 M | -15 M | -19 M | -13 M | -7 M | -7 M | -10 M | -11 M | -6 M |
| Minority floaterest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total net income | -7 M | -16 M | -15 M | -19 M | -13 M | -7 M | -7 M | -10 M | -11 M | -6 M |
| Preferred dividends | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 800000 | N/A | 735000 |
| Net income available for common | -7 M | -16 M | -15 M | -19 M | -13 M | -7 M | -7 M | -10 M | -11 M | -7 M |
| Depreciation | 341000 | 314000 | 232000 | 164000 | 114000 | 95000 | 266000 | 65000 | 51000 | 119000 |
| Amortization | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating income before depreciation (EBITDA) | -8 M | -15 M | -17 M | -21 M | -11 M | -7 M | -8 M | -9 M | -6 M | -9 M |
| Total Income available for floaterest expense (EBIT) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Basic EPS total | -6 | -10.5 | -7.75 | -6.82 | -1.4 | -0.48 | -0.39 | -0.48 | -0.31 | -0.15 |
| Diluted EPS total | -6 | -10.5 | -7.75 | -6.82 | -1.4 | -0.48 | -0.46 | -0.48 | -0.31 | -0.15 |
Call: 1-877-778-8358
I am so happy you are here. My name is Ankur and I am the founder/CEO of MarketXLS. Over the past four years, I have helped more than 2500 customers to implement their own investment research strategies and monitoring systems in Excel.
Invest with confidence with billions of data points and thousands of pre-built functions and templates.
Get started today
Get started today